2024-02-14 10:02:30
Clinical trial of existing treatment abatacept confirms preventive effect in high-risk groups
Entered 2024.02.14 19:00 Entered 2024.02.14 19:00 Modified 2024.02.14 16:47 Views 115
Rheumatoid arthritis is a chronic autoimmune disease that causes inflammation in the body and pain in the joints. [사진= 게티이미지뱅크]A new study has shown that prescribing existing rheumatoid arthritis (RA) treatments to high-risk groups for RA has a clear preventive and symptom-relieving effect. This is what the British Guardian reported based on a paper by British and Dutch researchers published in The Lancet on the 13th (local time).
RA is a chronic autoimmune disease that causes inflammation in the body and pain in the joints. According to the World Health Organization (WHO), as many as 18 million people worldwide suffer from RA. This disease, which usually begins in middle age but can also develop at a much younger age, is difficult to cure and there is no preventive treatment.
Researchers are currently conducting a clinical trial of the severe RA inhibitor abatacept in children and adults aged 6 years or older with the hope that it may slow the progression of RA in people with early symptoms. We recruited 213 patients diagnosed at risk for early RA from early arthritis clinics based at 28 hospitals in the UK and the Netherlands. Among them, 110 were injected with abatacept and the rest were injected with placebo.
The proportion of patients remaining arthritis-free at 12 months was 92.8% in the abatacept group and 69.2% in the placebo group. At 24 months, 25% (27 patients) of the abatacept group and 37% (38 patients) of the placebo group developed RA.
“This is the largest RA prevention clinical trial to date,” said Professor Andrew Cope of the Center for Rheumatology at King’s College London (UCK), who led the study. “It shows that existing RA treatments can prevent the development of the disease in people at risk of RA. “This is the first time we have shown that it is effective.” “Studies show that this drug can not only prevent the development of RA, but also relieve symptoms such as pain and fatigue,” he said. “The next step is to better understand who is most at risk of developing RA, so that we can be absolutely certain regarding prescribing this drug.” “The goal is to have it,” he said.
The study also showed other effects of abatacept treatment, including lower pain scores and improved quality of life in RA patients. One patient, Philip Day, 35, of London, England, was enrolled in a clinical trial in 2018 and received a prescription for abatacept. He was once a soccer fan and gave up kicking a ball due to joint pain, but now, five years later, he no longer has any pain or pain. “Now I can live a normal life, even playing soccer with my three-year-old son,” he said. .
Abatacept is a drug that regulates immunity by suppressing the activity of excessively activated T lymphocytes. When T lymphocytes recognize an antigen through an antigen fragment presented by an antigen-presenting cell (APC), they are activated and begin immune activity. Abatacept inhibits the activity of T lymphocytes by binding to specific membrane proteins of antigen-presenting cells and interfering with antigen recognition by T lymphocytes. It is administered by intravenous or subcutaneous injection and slows the progression of RA and prevents joint damage, alleviating symptoms. It takes approximately 3 to 6 months for the drug to take effect.
You can check the paper at the following link (
” ⓒ ‘Honest Knowledge for Health’ Comedy.com ( / Unauthorized reproduction and redistribution, AI learning and use prohibited”
1707909532
#Rheumatoid #arthritis #highrisk #group #preventable
